Clinical Trials · NCT05912621
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Stanford University
- Enrollment
- 66
- Start date
- Nov 2023
- Locations
- 1 site, United States
- Primary endpoint
- Change in Adipocyte Size